The pathophysiology of heart failure

被引:417
作者
Kemp, Clinton D. [1 ]
Conte, John V. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Div Cardiac Surg, Dept Surg, Baltimore, MD 21287 USA
关键词
Heart failure; Pathophysiology; ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES; HYPERTENSION; MANAGEMENT;
D O I
10.1016/j.carpath.2011.11.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure is a clinical syndrome that results when the heart is unable to provide sufficient blood flow to meet metabolic requirements or accommodate systemic venous return. This common condition affects over 5 million people in the United States at a cost of $10-38 billion per year. Heart failure results from injury to the myocardium from a variety of causes including ischemic heart disease, hypertension, and diabetes. Less common etiologies include cardiomyopathies, valvular disease, myocarditis, infections, systemic toxins, and cardiotoxic drugs. As the heart fails, patients develop symptoms which include dyspnea from pulmonary congestion, and peripheral edema and ascites from impaired venous return. Constitutional symptoms such as nausea, lack of appetite, and fatigue are also common. There are several compensatory mechanisms that occur as the failing heart attempts to maintain adequate function. These include increasing cardiac output via the Frank Starling mechanism, increasing ventricular volume and wall thickness through ventricular remodeling, and maintaining tissue perfusion with augmented mean arterial pressure through activation of neurohormonal systems. Although initially beneficial in the early stages of heart failure, all of these compensatory mechanisms eventually lead to a vicious cycle of worsening heart failure. Treatment strategies have been developed based upon the understanding of these compensatory mechanisms. Medical therapy includes diuresis, suppression of the overactive neurohormonal systems, and augmentation of contractility. Surgical options include ventricular resynchronization therapy, surgical ventricular remodeling, ventricular assist device implantation, and heart transplantation. Despite significant understanding of the underlying pathophysiological mechanisms in heart failure, this disease causes significant morbidity and carries a 50% 5-year mortality. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 24 条
[11]  
Hjalmarson Å, 1999, LANCET, V353, P2001
[12]   ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the evaluation and management of heart failure) [J].
Hunt, SA ;
Baker, DW ;
Chin, MH ;
Cinquegrani, MP ;
Feldman, AM ;
Francis, GS ;
Ganiats, TG ;
Goldstein, S ;
Gregoratos, G ;
Jessup, ML ;
Noble, RJ ;
Packer, M ;
Silver, MA ;
Stevenson, LW ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Jacobs, AK ;
Hiratzka, LF ;
Russell, RO ;
Smith, SC .
CIRCULATION, 2001, 104 (24) :2996-3007
[13]   2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J].
Hunt, Sharon Ann ;
Abraham, William T. ;
Chin, Marshall H. ;
Feldman, Arthur M. ;
Francis, Gary S. ;
Ganiats, Theodore G. ;
Konstam, Marvin A. ;
Mancini, Donna M. ;
Michl, Keith ;
Oates, John A. ;
Rahko, Peter S. ;
Silver, Marc A. ;
Stevenson, Lynne Warner ;
Yancy, Clyde W. ;
Jessup, Mariell ;
Casey, Donald E. .
CIRCULATION, 2009, 119 (14) :E391-E479
[14]   Natriuretic Peptide Testing in Heart Failure [J].
Kim, Han-Na ;
Januzzi, James L., Jr. .
CIRCULATION, 2011, 123 (18) :2015-2019
[15]   Current Concepts of Neurohormonal Activation in Heart Failure Mediators and Mechanisms [J].
Lee, Christopher S. ;
Tkacs, Nancy C. .
AACN ADVANCED CRITICAL CARE, 2008, 19 (04) :364-385
[16]  
Lilly L. S., 2011, PATHOPHYSIOLOGY HEAR
[17]   Lifetime risk for developing congestive heart failure - The Framingham Heart Study [J].
Lloyd-Jones, DM ;
Larson, MG ;
Leip, EP ;
Beiser, A ;
D'Agostino, RB ;
Kannel, WB ;
Murabito, JM ;
Vasan, RS ;
Benjamin, EJ ;
Levy, D .
CIRCULATION, 2002, 106 (24) :3068-3072
[18]  
Mohrman DE., 2010, CARDIOVASCULAR PHYSL, V7
[19]  
NHLBI, WHAT IS HEART FAIL
[20]   Renal hemodynamics in heart failure: implications for treatment [J].
Rea, Mark E. ;
Dunlap, Mark E. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (01) :87-92